Form 4: Verrica Pharmaceuticals Director, Gavin Corcoran, Acquires Stock Options

Gavin Corcoran, a director at Verrica Pharmaceuticals, acquired stock options for 17,502 shares on March 31, 2025, according to a Form 4 filing.

Summary

• Gavin Corcoran, a director of Verrica Pharmaceuticals Inc. (VRCA), filed a Form 4 indicating a change in beneficial ownership.
• On March 31, 2025, Corcoran acquired stock options for 17,502 shares of VRCA common stock at an exercise price of $0.44.
• The options vest over time, with one-third vesting on March 31, 2026, and the remaining two-thirds vesting in 24 monthly installments thereafter, contingent upon continuous service.
• Following the transaction, Corcoran directly owns 17,502 shares underlying the options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director is generally a good sign, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a long-term incentive for the director to remain with the company and contribute to its success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to track the buying and selling activity of individuals with privileged information about the company's prospects.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, Verrica Pharmaceuticals, VRCA, Stock Options, Gavin Corcoran, Director, Beneficial Ownership